12.60
price up icon1.86%   0.23
pre-market  プレマーケット:  12.65   0.05   +0.40%
loading
前日終値:
$12.37
開ける:
$12.4
24時間の取引高:
3.19M
Relative Volume:
0.59
時価総額:
$1.76B
収益:
$67.67M
当期純損益:
$-412.69M
株価収益率:
-3.2927
EPS:
-3.8266
ネットキャッシュフロー:
$-395.87M
1週間 パフォーマンス:
-7.83%
1か月 パフォーマンス:
-23.96%
6か月 パフォーマンス:
+53.47%
1年 パフォーマンス:
+33.19%
1日の値動き範囲:
Value
$12.35
$12.89
1週間の範囲:
Value
$11.79
$13.88
52週間の値動き範囲:
Value
$6.83
$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1106)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
377
Name
Twitter
@intelliatweets
Name
次回の収益日
2026-05-14
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NTLA icon
NTLA
Intellia Therapeutics Inc
12.60 1.73B 67.67M -412.69M -395.87M -3.8266
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
434.52 110.03B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
638.88 67.37B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
806.46 50.76B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
297.45 40.12B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
151.56 32.68B 742.00K -1.37B -1.07B -7.0731

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-02 アップグレード William Blair Mkt Perform → Outperform
2025-11-12 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-11 ダウングレード Evercore ISI Outperform → In-line
2025-11-07 ダウングレード JP Morgan Neutral → Underweight
2025-10-28 ダウングレード Bernstein Outperform → Mkt Perform
2025-10-28 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-10-27 ダウングレード Guggenheim Buy → Neutral
2025-10-27 ダウングレード William Blair Outperform → Mkt Perform
2025-10-06 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-04-21 アップグレード Wolfe Research Peer Perform → Outperform
2025-03-05 開始されました H.C. Wainwright Buy
2025-02-28 ダウングレード Goldman Neutral → Sell
2025-02-28 ダウングレード JP Morgan Overweight → Neutral
2025-01-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
May 25, 2026

Avoiding Lag: Real-Time Signals in (NTLA) Movement - Stock Traders Daily

May 25, 2026
pulisher
May 24, 2026

Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - MSN

May 24, 2026
pulisher
May 22, 2026

Chardan Capital Maintains Intellia Therapeutics (NTLA) Buy Recommendation - MSN

May 22, 2026
pulisher
May 21, 2026

Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout

May 21, 2026
pulisher
May 20, 2026

Intellia Drops Counterclaims In Gene-Editing Patent Case - Law360

May 20, 2026
pulisher
May 20, 2026

Intellia Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus

May 20, 2026
pulisher
May 20, 2026

Intellia Dismisses Four Counterclaims in BlueAllele Patent Suit - Bloomberg Law News

May 20, 2026
pulisher
May 20, 2026

Intellia Therapeutics’ SWOT analysis: gene-editing stock faces regulatory test By Investing.com - Investing.com Nigeria

May 20, 2026
pulisher
May 19, 2026

Intellia Therapeutics’ SWOT analysis: gene-editing stock faces regulatory test - Investing.com

May 19, 2026
pulisher
May 19, 2026

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - Yahoo Finance

May 19, 2026
pulisher
May 19, 2026

Does Intellia Therapeutics (NTLA) Cash Runway Truly Offset Dilution Concerns From Its Recent Equity Raise? - Sahm

May 19, 2026
pulisher
May 19, 2026

Buy the Rumor, Sell the News: Intellia (NTLA) Falls After Landmark Phase 3 Win - CoinCentral

May 19, 2026
pulisher
May 17, 2026

Intellia Therapeutics FDA rolling application for gene therapy puts hype to test - MSN

May 17, 2026
pulisher
May 17, 2026

Intellia Therapeutics says its CRISPR-based treatment succeeds in pivotal trial - MSN

May 17, 2026
pulisher
May 17, 2026

NTLA Q1 earnings beat estimates, revenues miss mark, pipeline in focus - MSN

May 17, 2026
pulisher
May 15, 2026

A Look At Intellia Therapeutics (NTLA) Valuation After Recent Gene Editing Trial And BLA Progress - Sahm

May 15, 2026
pulisher
May 14, 2026

Intellia Therapeutics (NTLA) slides as investors digest recent earnings and dilution overhang - Quiver Quantitative

May 14, 2026
pulisher
May 14, 2026

Discipline and Rules-Based Execution in NTLA Response - Stock Traders Daily

May 14, 2026
pulisher
May 14, 2026

Earnings Update: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st

May 14, 2026
pulisher
May 14, 2026

Intellia Therapeutics, Inc. (NASDAQ:NTLA) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

May 14, 2026
pulisher
May 14, 2026

Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline - Sahm

May 14, 2026
pulisher
May 14, 2026

Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail

May 14, 2026
pulisher
May 14, 2026

NTLA Maintained by Bernstein -- Price Target Raised to $17.00 - GuruFocus

May 14, 2026
pulisher
May 13, 2026

A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $25 - Moomoo

May 13, 2026
pulisher
May 13, 2026

NTLA Maintains by HC Wainwright & Co. -- Price Target Lowered to $25 - GuruFocus

May 13, 2026
pulisher
May 13, 2026

Wedbush Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail

May 13, 2026
pulisher
May 13, 2026

H.C. Wainwright cuts Intellia Therapeutics stock price target to $25 on dilution - Investing.com Australia

May 13, 2026
pulisher
May 13, 2026

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail

May 13, 2026
pulisher
May 13, 2026

H.C. Wainwright cuts Intellia Therapeutics stock price target to $25 on dilution By Investing.com - Investing.com South Africa

May 13, 2026
pulisher
May 13, 2026

RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA) - The Globe and Mail

May 13, 2026
pulisher
May 13, 2026

High Growth Tech Stocks In The US For May 2026 - simplywall.st

May 13, 2026
pulisher
May 13, 2026

NTLA stock rockets after hours before critical data for genetic disorder therapy - MSN

May 13, 2026
pulisher
May 13, 2026

Intellia Therapeutics Price Target Cut to $49.00/Share From $58.00 by Canaccord Genuity - Moomoo

May 13, 2026
pulisher
May 12, 2026

Transcript : Intellia Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03 - marketscreener.com

May 12, 2026
pulisher
May 12, 2026

Cathie Wood’s ARK sells Twist Bioscience stock, buys Intellia shares - Investing.com

May 12, 2026
pulisher
May 12, 2026

Cathie Wood’s ARK sells Twist Bioscience stock, buys Intellia shares By Investing.com - Investing.com India

May 12, 2026
pulisher
May 12, 2026

Intellia Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus

May 12, 2026
pulisher
May 12, 2026

BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $19 - Moomoo

May 12, 2026
pulisher
May 12, 2026

NTLA SEC FilingsIntellia Therape 10-K, 10-Q, 8-K Forms - Stock Titan

May 12, 2026
pulisher
May 12, 2026

NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus - TradingView

May 12, 2026
pulisher
May 12, 2026

NTLA Reiterated by Wedbush -- Price Target Maintained at $12 - GuruFocus

May 12, 2026
pulisher
May 12, 2026

Intellia short interest rises most among biotech stocks in latest periodBaird - Investing.com

May 12, 2026
pulisher
May 12, 2026

Intellia Therapeutics Stock Short Interest Rises to 39.28% - Quiver Quantitative

May 12, 2026
pulisher
May 12, 2026

NTLA jumps premarket on positive late-stage trial data for gene-editing therapy — retail says buy now before it’s too late - MSN

May 12, 2026
pulisher
May 12, 2026

How Investors May Respond To Intellia Therapeutics (NTLA) Raising Capital And Advancing Its CRISPR HAE Therapy - Sahm

May 12, 2026
pulisher
May 12, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 12, 2026
pulisher
May 12, 2026

Intellia Therapeutics Inc earnings beat by $0.10, revenue topped estimates - Investing.com South Africa

May 12, 2026
pulisher
May 12, 2026

NTLA SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus

May 12, 2026
pulisher
May 11, 2026

$Intellia Therapeutics (NTLA.US)$ Need to drop to 14 bf it take off.. - Moomoo

May 11, 2026
pulisher
May 11, 2026

Intellia Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo

May 11, 2026
pulisher
May 11, 2026

Intellia (NTLA) Reports Strong Q1 Revenue and Achievements in Ge - GuruFocus

May 11, 2026

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Intellia Therapeutics Inc (NTLA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Clark Eliana
EVP, Chief Technical Officer
Mar 02 '26
Sale
13.78
607
8,364
93,864
LEONARD JOHN M
President and CEO
Jan 05 '26
Sale
9.21
34,146
314,485
1,013,339
Schultes Birgit C
EVP, Chief Scientific Officer
Jan 05 '26
Sale
9.21
8,508
78,359
98,533
BASTA JAMES
EVP, General Counsel
Jan 05 '26
Sale
9.21
10,397
95,756
101,528
Cohen Fred E
Director
Jan 05 '26
Buy
9.35
150,000
1,402,500
207,453
Lebwohl David
EVP, Chief Medical Officer
Jan 05 '26
Sale
9.21
11,903
109,627
121,249
Clark Eliana
EVP, Chief Technical Officer
Jan 05 '26
Sale
9.21
9,515
87,633
87,118
Dulac Edward J III
EVP, Chief Financial Officer
Jan 05 '26
Sale
9.21
6,379
58,751
99,683
Dube Michael P
VP, Chief Accounting Officer
Jan 05 '26
Sale
9.21
2,989
27,529
52,277
LEONARD JOHN M
President and CEO
Dec 11 '25
Option Exercise
6.83
49,959
341,220
1,127,074
$29.96
price down icon 2.98%
$106.24
price down icon 3.00%
$92.14
price up icon 1.33%
$54.50
price up icon 1.77%
ONC ONC
$310.25
price up icon 0.20%
$151.56
price down icon 1.41%
大文字化:     |  ボリューム (24 時間):